Zusammenfassung
Der vasodilatorische Schock ist die häufigste Schockform des Intensivpatienten. Als Folge übermäßiger und prolongierter Mediatorproduktion kann der vasodilatorische Schock auch aus primär nichtvasodilatorischen Schockzuständen (z. B. kardiogener oder hypovolämer Schock) entstehen. Eine zusätzliche Infusion mit Arginin Vasopressin (AVP) zeigte vorteilhafte Effekte auf die Hämodynamik und wahrscheinlich auch das Outcome bei Patienten mit vasodilatorischem Schock durch Sepsis oder nach großen chirurgischen Eingriffen. In dieser Fallsammlung wird über die erfolgreiche Anwendung von AVP bei drei chirurgischen Intensivpatienten mit primär kardiogenen Schockzuständen berichtet. Die hämodynamischen Effekte von AVP waren den im septischen Schock berichteten AVP-induzierten Veränderungen sehr ähnlich. Diese scheinen auch bei den beschriebenen Patienten maßgeblich durch die potente Vasokonstriktion sowie die ermöglichte Reduktion hoher, potenziell toxischer Katecholamindosierungen bedingt zu sein. Dabei dürfte gerade die AVP-vermittelte Reduktion der Herzfrequenz und der pulmonalarteriellen Drücke bei Patienten mit eingeschränkter kardialer Funktion von Vorteil sein.
Abstract
Vasodilatory shock is the most common form of shock in the critically ill patient. As a consequence of overwhelming and prolonged mediator production, vasodilatory shock can be the common final pathway of primary non-vasodilatory shock (e.g. cardiogenic or hypovolemic shock). A supplementary infusion of arginine vasopressin (AVP) showed beneficial effects on hemodynamics and potentially on the outcome in patients with vasodilatory shock due to sepsis or after major surgery. In this case series, successful administration of AVP in three surgical patients with primary cardiogenic shock forms is reported. The hemodynamic effects of AVP were comparable to those AVP-induced alterations described in septic shock and seem to be predominantly mediated by potent vasoconstriction and the facilitated reduction of higher, potentially toxic catecholamine doses. Thus, an AVP-induced decrease in heart rate and pulmonary arterial pressures may be particularly beneficial in patients with impaired cardiac function.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Asfar P, Hauser B, Radermacher P, Matejovic M (2006) Catecholamines and vasopressin during critical illness. Crit Care Clin 22: 131–149
Bayram M, De Luca L, Massie MB, Gheorghiade M (2005) Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96: 47–58
Braun EB, Palin CA, Hogue CW (2004) Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol. Anesth Analg 99: 36–37
Dünser MW, Mayr AJ, Ulmer H et al. (2001) The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 93: 7–13
Dünser MW, Mayr AJ, Stallinger A et al. (2002) Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 28: 746–751
Dünser MW, Wenzel V, Mayr AJ, Hasibeder WR (2003) Management of vasodilatory shock: defining the role of arginine vasopressin. Drugs 63: 237–256
Dünser MW, Mayr AJ, Ulmer H et al. (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107: 2313–2319
Dünser MW, Fries DR, Schobersberger W et al. (2004) Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg 99: 201–206
Eichinger MR, Walker BR (1994) Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol 276: H2413–2419
Evora PR, Pearson PJ, Schaff HV (1993) Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 103: 1241–1245
Gold JA, Cullinane S, Chen J et al. (2000) Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med 28: 249–252
Jolly S, Newton G, Horlick E et al. (2005) Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 96: 1617–1620
Landry DW, Levin HR, Gallant EM et al. (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25: 1279–1282
Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345: 588–595
Leather HA, Segers P, Berends N et al. (2002) Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 30: 2548–2552
Luckner G, Dünser MW, Jochberger S et al. (2005) Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33: 2659–2666
Mann HJ, Nolan PE Jr (2006) Update on the management of cardiogenic shock. Curr Opin Crit Care 12: 431–436
Mutlu GM, Factor P (2004) Role of vasopressin in the management of septic shock. Intensive Care Med 30: 1276–1291
Wang HJ, Wong CS, Chiang CY et al. (2003) Low-dose vasopressin infusion can be an alternative in treating patients with refractory septic shock combined with chronic pulmonary hypertension: a case report. Acta Anaesthesiol Sin 41: 77–80
Westphal M, Stubbe H, Sielenkämper AW et al. (2003) Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 29: 301–308
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mayr, V., Luckner, G., Jochberger, S. et al. Vasopressin als Reservevasopressor. Anaesthesist 56, 1017–1023 (2007). https://doi.org/10.1007/s00101-007-1227-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00101-007-1227-4